Compare ACIW & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACIW | APGE |
|---|---|---|
| Founded | 1975 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.7B |
| IPO Year | 1996 | 2023 |
| Metric | ACIW | APGE |
|---|---|---|
| Price | $41.87 | $87.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | $62.50 | ★ $109.67 |
| AVG Volume (30 Days) | 685.8K | ★ 791.9K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 13.09 | N/A |
| EPS | ★ 2.16 | N/A |
| Revenue | ★ $1,009,780,000.00 | N/A |
| Revenue This Year | $9.67 | N/A |
| Revenue Next Year | $7.41 | N/A |
| P/E Ratio | $20.45 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $38.05 | $34.34 |
| 52 Week High | $55.45 | $95.32 |
| Indicator | ACIW | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 49.96 | 59.90 |
| Support Level | $38.70 | $73.06 |
| Resistance Level | $43.01 | N/A |
| Average True Range (ATR) | 1.34 | 3.36 |
| MACD | 0.23 | -0.08 |
| Stochastic Oscillator | 39.16 | 48.34 |
ACI Worldwide Inc develops, markets, and installs a portfolio of software products focused on facilitating electronic payments. The firm's products are sold and supported directly and through distribution networks covering three geographic regions - the Americas, EMEA, and Asia Pacific. ACI software products process payment transactions for retail banking clients, billers such as utilities and healthcare providers, and community banks and credit unions. ACI's customers are financial institutions all over the world, but the majority of the revenue is generated in the United States and EMEA regions. The company's operating segment includes Payment Software and Biller. The company generates the majority of its revenue from the Payment Software segment.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.